阻塞性睡眠呼吸暂停综合征与代谢性疾病的机制及诊疗进展

刘 青红
青海大学

摘要


阻塞性睡眠呼吸暂停（Obstructive Sleep Apnea，OSA）是一种常见睡眠呼吸障碍，近年来被认为与代谢综合征（Metabolic Syndrome，MetS）密切相关。而OSA和MetS是多种慢性疾病的共同病理基础。本文将通过OSA与MetS及其相关代谢性疾病的流行病学、病理机制及治疗措施等方面进行论述。

关键词


阻塞性睡眠呼吸暂停；代谢综合征；肥胖；高血压；2型糖尿病；血脂紊乱；非酒精性脂肪性肝病；间歇性低氧；持续气道正压通气

全文:

PDF


参考


[1]Lyons MM, Bhatt NY, Pack AI, et al.Global burden of sleep-disordered breathing and its implications[J].Respirology, 2020, 25(7):690-702

[2]Saklayen M G.The global epidemic of the metabolic syndrome[J].Curr Hypertens Rep, 2018, 20(2):12.

[3]Yao F, Bo Y, Zhao L, Li Y, Ju L, Fang H, Piao W, Yu D, Lao X. Prevalence and influencing factors of metabolic syndrome among adults in China from 2015 to 2017 [J]. Nutrients, 2021, 13(12): 4475.

[4]阻塞性睡眠呼吸暂停合并代谢综合征诊疗专家共识组.阻塞性睡眠呼吸暂停合并代谢综合征诊疗专家共识（2022）[J].中华耳鼻咽喉头颈外科杂志，2023，58（2）：99-110.

[5]Tuomilehto H, SeppäJ, Uusitupa M.Obesity and obstructive sleep apnea—clinical significance of weight loss[J].Sleep Med Rev, 2013, 17(5):321-329.

[6]Carneiro-Barrera A, Amaro-Gahete F J, Guillén-Riquelme A, et al.Effect of an interdisciplinary weight loss and lifestyle intervention on obstructivesleep apnea severity:the INTERAPNEA randomized clinical trial[J].JAMA Netw Open, 2022, 5(4):e228212.

[7]Gottlieb D J.Screening for obstructive sleep apnea in adults[J].JAMA, 2022, 328(19):1908-1910.

[8]Xu X, Xu J, Zhang M. Association between metabolic score for visceral fat and obstructive sleep apnea: a cross-sectional study [J]. Front Med (Lausanne), 2024, 11: 1480717.

[9]McNicholas W T, Hansson D, Schiza S, et al. Sleep in chronic respiratory disease: COPD and hypoventilation disorders [J]. Eur Respir Rev, 2019, 28(153): 190064.

[10]Tietjens J R, Claman D, Kezirian E J, et al.Obstructive sleep apnea in cardiovascular disease:a review of the literature and proposed multidisciplinary clinical management strategy[J].J Am Heart Assoc, 2019, 8(1):e010440.

[11]Shiina K.Obstructive sleep apnea-related hypertension:a review of the literature and clinical management strategy[J].Hypertens Res, 2024, 47(11):3085-3098.

[12]Yazan S, Karakurt H, Püşüroğlu H.Relationship between obstructive sleep apnea severity and serum endocan levels in patients with hypertension[J].Tex Heart Inst J, 2023, 50(1):e217664.

[13]Abdel-Fadeil M R, Abedelhaffez A S, Makhlouf H A, et al.Obstructive sleep apnea:influence of hypertension on adiponectin, inflammatory markers and dyslipidemia[J].Pathophysiology, 2017, 24(4):305-315.

[14]McEvoy R D, Antic N A, Heeley E, et al.CPAP for prevention of cardiovascular events in obstructive sleep apnea[J].N Engl J Med, 2016, 375(10):919-931.

[15]Shiina K.Obstructive sleep apnea-related hypertension:a review of the literature and clinical management strategy[J]. Hypertens Res, 2024, 47(11):3085-3098.

[16]Fallahi A, Jamil DI, Karimi EB, et al.Prevalence of obstructive sleep apnea in patients with type 2 diabetes:a systematic review and meta-analysis[J].Diabetes Metab Syndr, 2019, 13(4):2463-2468.

[17]Prabhakar NR, Peng YJ, Nanduri J, et al.Hypoxia-inducible factors and obstructive sleep apnea[J].J Clin Invest, 2020, 130(10):5042-5051.

[18]OrrùG, Storari M, Scano A, et al.Obstructive sleep apnea, oxidative stress, inflammation and endothelial dysfunction—an overview of predictive laboratory biomarkers[J].Eur Rev Med Pharmacol Sci, 2020, 24(12): 6939-6948.35.

[19]Herth J, Sievi NA, Schmidt F, et al. Effects of continuous positive airway pressure therapy on glucose metabolism in patients with obstructive sleep apnoea and type 2 diabetes: a systematic review and meta-analysis[J]. Eur Respir Rev, 2023, 32(169): 230083.

[20]Jiang W, Li W, Cheng J, et al.Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea[J].Sleep Breath, 2023, 27(5):1687-1694.

[21]Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, et al. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol[J]. BMJ Open, 2021, 11(12): e049662.

[22]Bajpai J, Pradhan A, Bajaj D, et al.Prevalence of dyslipidaemia in OSA patients at a tertiary care center[J].Am J Cardiovasc Dis, 2023, 13(1):1-9.

[23]Bettini S, Serra R, Fabris R, et al.Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity:an observational study[J].Eat Weight Disord, 2022, 27(1):335-343.

[24]Wang L, Liu H, Zhou L, et al.Association of obstructive sleep apnea with nonalcoholic fatty liver disease: evidence, mechanism, and treatment[J]. Nat Sci Sleep, 2024, 16: 917-933.

[25]Tang H, Lv F, Zhang P, et al.The impact of obstructive sleep apnea on nonalcoholic fatty liver disease[J].Front Endocrinol(Lausanne), 2023, 14:1254459.

[26]Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3): 912-918

[27]Ng SSS, Wong VWS, Wong GLH, et al. Continuous positive airway pressure does not improve nonalcoholic fatty liver disease in patients with obstructive sleep apnea: a randomized clinical trial[J]. Am J Respir Crit Care Med, 2021, 203(4): 493-501.

[28]Alkhouri N, Charlton M, Gray M, et al.The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis:a review for gastroenterologists[J].Expert Opin Investig Drugs, 2025, 34(3):169-195

[29]Wilson R, Aminian A, Tahrani AA. Metabolic surgery: a clinical update[J]. Diabetes Obes Metab, 2021, 23(Suppl 1): 63-83.

[30]Zhang YX, Yang L, Yang CC, et al. Correlation between obstructive sleep apnea and non-alcoholic fatty liver disease before and after metabolic bariatric surgery[J]. Obes Surg, 2020, 30(10): 3803-3812.


Refbacks

  • 当前没有refback。